Dementia
Dementia
At CIC Neurosciences, we conduct three types of studies: therapeutic studies (both industry-sponsored and academic), and pathophysiological studies aimed at unraveling the fundamental mechanisms of diseases in order to advance our understanding and improve patient care.
Industrial therapeutic studies
Academic therapeutic studies
Pathophysiological Studies
CNIO752B12201
A randomized, double-blind, placebo-controlled study to evaluate the ability of a single dose of NIO752, administered intrathecally, to reduce total tau protein levels in the cerebrospinal fluid of patients with Alzheimer’s disease
🎯: To evaluate the ability of NIO752, compared with a placebo, to reduce total tau protein levels in the cerebrospinal fluid (CSF) of patients with early-stage Alzheimer’s disease following a single intrathecal injection of 100 mg or 200 mg.
📝: Currently being monitored
ECOCAPTURE @ HOME
Program to assess, in real-life settings, behavioral markers of apathy associated with brain disorders in patient-caregiver pairs and pairs of healthy volunteers
🎯: To validate a measurement model for the three putative behavioral markers of apathy: 1) activity level, 2) sleep quality, and 3) emotional reactivity, based on “passive behavioral data” and “active behavioral data” collected from dyads (patient-caregiver pairs and controls) over a 28-day period.
⏳: Currently being added
PET-AL
Mechanisms of neural resilience in Alzheimer’s disease and its focal variants: a PET/MRI study
🎯: To identify "resilient" neural networks and quantify the extent of damage (i.e., brain vulnerability) in Alzheimer's disease (AD) and post-stroke cognitive impairment (PSCI), through the study of anatomical and functional connectivity and its interaction with tau-related pathological burden. This interaction could represent the anatomical-functional substrate of neural resilience developed by ACP patients and lacking in MA-J patients.
⏳: Currently being added
At CIC Neurosciences, we conduct three types of studies: therapeutic studies (both industry-sponsored and academic), and pathophysiological studies aimed at unraveling the fundamental mechanisms of diseases in order to advance our understanding and improve patient care.
Industrial therapeutic studies
CNIO752B12201
A randomized, double-blind, placebo-controlled study to evaluate the ability of a single dose of NIO752, administered intrathecally, to reduce total tau protein levels in the cerebrospinal fluid of patients with Alzheimer’s disease
🎯: To evaluate the ability of NIO752, compared with a placebo, to reduce total tau protein levels in the cerebrospinal fluid (CSF) of patients with early-stage Alzheimer’s disease following a single intrathecal injection of 100 mg or 200 mg.
📝: Currently being monitored
Pathophysiological Studies
ECOCAPTURE @ HOME
Program to assess, in real-life settings, behavioral markers of apathy associated with brain disorders in patient-caregiver pairs and pairs of healthy volunteers
🎯: To validate a measurement model for the three putative behavioral markers of apathy: 1) activity level, 2) sleep quality, and 3) emotional reactivity, based on “passive behavioral data” and “active behavioral data” collected from dyads (patient-caregiver pairs and controls) over a 28-day period.
⏳: Currently being added
PET-AL
Mechanisms of neural resilience in Alzheimer’s disease and its focal variants: a PET/MRI study
🎯: To identify "resilient" neural networks and quantify the extent of damage (i.e., brain vulnerability) in Alzheimer's disease (AD) and post-stroke cognitive impairment (PSCI), through the study of anatomical and functional connectivity and its interaction with tau-related pathological burden. This interaction could represent the anatomical-functional substrate of neural resilience developed by ACP patients and lacking in MA-J patients.
⏳: Currently being added